Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MAXZIDE AND DYAZIDE COMPARATIVE DOSAGES

Executive Summary

Reproduced by "The Pink Sheet" from initial labeling for Maxzide and most recent PDR labeling version for Dyazide. MAXZIDE DOSAGE AND ADMINISTRATION -- The recommended dosage of MAZXIDE is one tablet daily with appropriate monitoring of serum potassium levels (see WARNINGS). Patients receiving 50 mg of hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE directly. In patients requiring 50 mg of hydrochlorothiazide in whom hypokalemia cannot be risked, therapy may be initiated with MAXZIDE. There is no clinical experience with doses exceeding one tablet daily. Clinical studies have shown that patients already taking less bioavailable formulations of triamterene and hydrochlorothiazide (totaling 50-100 mg of hydrochlorothiazide and 100-200 mg of triamterene) may be safely changed to one MAXZIDE tablet per day.; these patients should be monitored clinically and with serum potassium after the transfer. DYAZIDE DOSAGE AND ADMINISTRATION -- As determined by individual titration. Adults: The usual dose is one or two capsules twice daily after meals. Some patients may be maintained on one capsule daily or every other day. Maximum daily dose should not exceed four capsules, and at this dosage, the incidence of side effects may increase. Since 'Dyazide' has an antihypertensive effect, hypotensive drugs used concomitantly should be added at reduced dosage -- at least one half the usual dosage -- particularly if it is a ganglionic or peripheral adrenergic blocking agent. Adjust dosage as indicated. Children: Adequate information on the use of 'Dyazide' in children is not available. Note: Potassium supplementation used concurrently with other diuretics should be discontinued when titrating with Dyrenium (triamterene, SK&F Co.). They should not be reinstituted when the patient is placed on 'Dyazide' unless the triamterene component does not completely compensate for the potassium loss.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel